Sign in to fuzzto save your conversations, follow your research and come back anytime.
Tarsons Products
TARSONS
NSE
BSE
NSEBSESectorHealthcare
336.50
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Tarsons Products shows strong standalone cash generation and export growth, but consolidated profits face seasonal pressure and margin compression.
Standalone revenue grew from ₹71.3 Cr to ₹84.0 Cr from Q1 to Q3 FY26 — steady top-line momentum.
Consolidated PAT margin fell from 2.0% to -1.3% from Q1 FY26 to Q1 FY27 — sharp profitability erosion.
Standalone EBITDA margin improved from 31.2% to 34.7% from Q1 to Q3 FY26 — strong pricing power.
Consolidated gross margin declined from 67.9% to 64.9% from Q1 FY26 to Q1 FY27 — pricing pressure on core products.
Export revenue mix rose from 47% to 51% from Q1 to Q3 FY26 — overseas demand strength.
Consolidated EBITDA contracted from ₹34.3 Cr to ₹26.0 Cr from Q4 FY26 to Q1 FY27 — seasonal demand swings.
Standalone cash PAT climbed from ₹21.3 Cr to ₹31.9 Cr from Q1 to Q4 FY26 — robust operational cash generation.
Consolidated finance cost rose from ₹5.1 Cr to ₹6.3 Cr from Q1 FY26 to Q1 FY27 — higher debt servicing burden.